Abstract: The present invention relates to monoclonal antibodies that specifically bind to HER2, or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer specific HER2 binding to the polypeptide. Said antibodies bind to the human Fc receptor and induce FcR mediated signaling pathways. The antibodies according to the invention bind to a different epitope than trastuzumab. The invention also relates to the use of an antibody according to the invention in the treatment of a HER-2 mediated disease. The present invention also relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention, and the use of said composition in the treatment of a HER-2 mediated disease.

Abstract: The present disclosure relates to humanized antibodies that specifically bind to IL-1R3 or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer IL-1R3 binding specificity. Said antibodies inhibit IL-1R3 induced NFkB activity. They also inhibit IL-1alpha, IL-1beta, IL-33, and/or IL-36 stimulated NFkB activity. The disclosure further relates to use of said humanized antibody in the treatment of an IL-1R3 mediated disease such as cancer. The disclosure finally encompasses a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention. The pharmaceutical composition can be used in treating a IL-1R3 mediated disease such as cancer.

Abstract: Monoclonal antibody that specifically binds IL-1RAcP, or an antigen binding fragment thereof, comprising: a) a heavy chain variable region (VH) comprising CDR1H, CDR2H and/or CDR3H, wherein the CDR1H region comprises an amino acid sequence selected from the group of SEQ ID NO: 155-231, wherein the CDR2H region comprises an amino acid sequence selected from the group of SEQ ID NO: 232-308, and wherein the CDR3H region comprises an amino acid sequence selected from the group of SEQ ID NO: 309-385; and b) a light chain variable region (VL) comprising CDR1L, CDR2L and/or CDR3L, wherein the CDR1L region comprises an amino acid sequence selected from the group of SEQ ID NO: 386-462, wherein the CDRL2 region comprises an amino acid sequence selected from the group of SEQ ID NO: 463-539, and wherein the CDR3L region comprises an amino acid sequence selected from the group of SEQ ID NO: 540-616 The monoclonal antibody is characterized in that it inhibits IL-1RAcP induced NFkB activity, useful in treatment of IL-1RAcP

Abstract: In the case of a method or an arrangement for the automatic start up of a first communication terminal (EG A, EG B) configured for voice communication on at least one second communication terminal (CL A, CL B) configured for text communication, the voice communication between communication terminals is conveyed via at least one voice communication server (SCS) and the text communication between communication terminals is conveyed via at least one text communication server (TCS). The at least one voice communication server (SCS) and the at least one text communication server (TCS) exchange information via at least one conversion device (GW). The start up of at least one first communication terminal (CL A, CL B) is effected via the at least one text communication server (TCS), the at least one conversion device (GW) and the at least one voice communication server (SCS) to at least one second voice communication terminal (EG A, EG B).

Abstract: A drive system for a motor vehicle includes a separating clutch, a shiftable transmission, a drive machine, and a transmission gear wheel and a clutch device. In a first operating state either the clutch device or the transmission gear wheel is kinematically coupled to the transmission input shaft and in a second operating state both said clutch device and said transmission gear wheel are kinematically coupled in said manner thereto. The drive system comprises a braking device for transmitting a braking force in a non-contact manner in this first operating state from a first part to a second part of the braking device. In that the first part of the braking device is kinematically coupleable to the transmission input shaft and the second part is kinematically coupleable to the transmission gear wheel.

Abstract: The present invention relates to monoclonal antibodies that specifically bind to HER2, or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer specific HER2 binding to the polypeptide. Said antibodies bind to the human Fc receptor and induce FcR mediated signaling pathways. The antibodies according to the invention bind to a different epitope than trastuzumab. The invention also relates to the use of an antibody according to the invention in the treatment of a HER-2 mediated disease. The present invention also relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention, and the use of said composition in the treatment of a HER-2 mediated disease.

Abstract: The present disclosure relates to nesting sub-spaces for a machine tool by reading in evaluation criteria for an arrangement of nested sub-spaces, generating sequence data for an arrangement of nested sub-spaces, repeatedly performing a process until the result data exceeds a specified range. The process includes: generating evaluation data by evaluating the sequence data with an evaluation algorithm, generating result data based on a combinatorial logic of the evaluation data with the evaluation criteria, generating calculation data from the sequence data, the evaluation data, and the result data using the evaluation algorithm, generating further sequence data taking into account the calculation data with the evaluation algorithm, and repeating the process until the result data exceeds a specified range. The calculation data acts onto the generation of new sequence data to improve an arrangement of nested sub-spaces with respect to evaluation criteria.

Abstract: A method for operating a rotating-mass device and a rotating mass device of a two-wheeled vehicle are provided. The rotating-mass device includes first and second gyroscopic instruments, each with a cardanically mounted rotating-mass device suitable for generating torque about their respective rotation axes. Pivoting of the rotating-mass devices is coordinated to influence motion of the two-wheeled vehicle about three orthogonal vehicle axes.

Abstract: The present invention relates to monoclonal antibodies that specifically bind to human IL-1 R7, or a fragment or derivative thereof or a polypeptide that contain at least a portion of said antibody that is sufficient to confer specific IL-1 R7 binding to the polypeptide. The invention also relates to the use of said antibodies in the treatment of a IL-18 mediated disease and pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention.

Abstract: Monoclonal antibody that specifically binds the interleukin 1 receptor type 1 (IL-1RAcP), or an antigen binding fragment thereof, comprising: a) a heavy chain variable region (VH) comprising CDR1H, CDR2H and/or CDR3H, wherein the CDR1H region comprises an amino acid sequence selected from the group of SEQ ID NO: 155-231, wherein the CDR2H region comprises an amino acid sequence selected from the group of SEQ ID NO: 232-308, and wherein the CDR3H region comprises an amino acid sequence selected from the group of SEQ ID NO: 309-385; and b) a light chain variable region (VL) comprising CDR1L, CDR2L and/or CDR3L, wherein the CDR1L region comprises an amino acid sequence selected from the group of SEQ ID NO: 386-462, wherein the CDRL2 region comprises an amino acid sequence selected from the group of SEQ ID NO: 463-539, and wherein the CDR3L region comprises an amino acid sequence selected from the group of SEQ ID NO: 540-616.

Abstract: Monoclonal antibody that specifically binds IL-1RAcP, or an antigen binding fragment thereof, comprising: a) a heavy chain variable region (VH) comprising CDR1H, CDR2H and/or CDR3H, wherein the CDR1H region comprises an amino acid sequence selected from the group of SEQ ID NO: 155-231, wherein the CDR2H region comprises an amino acid sequence selected from the group of SEQ ID NO: 232-308, and wherein the CDR3H region comprises an amino acid sequence selected from the group of SEQ ID NO: 309-385; and b) a light chain variable region (VL) comprising CDR1L, CDR2L and/or CDR3L, wherein the CDR1L region comprises an amino acid sequence selected from the group of SEQ ID NO: 386-462, wherein the CDRL2 region comprises an amino acid sequence selected from the group of SEQ ID NO: 463-539, and wherein the CDR3L region comprises an amino acid sequence selected from the group of SEQ ID NO: 540-616 The monoclonal antibody is characterized in that it inhibits IL-1RAcP induced NF?B activity, useful in treatment of IL-

Abstract: The invention relates to production planning systems and methods. A production optimization system is provided which has the following: a production environment with at least one first machine, a second machine, a distribution unit configured to be connected to the first machine and the second machine via a communication network and to ascertain the machine state thereof, and an optimization unit configured to generate a production plan where at least one task for producing a product is separated into machine-specific sub-tasks for the first machine or the second machine, said sub-tasks being provided with a sequence for the first machine or the second machine. The distribution unit ascertains the next occurring sub-task for the first machine or the second machine from the optimization unit while taking into consideration the respective machine state, to remove the sub-task from the production plan, and to assign the sub-task to the respective machine.

Abstract: A diaphragm for a container assembly for dispensing products such as wipes or sheets, or collecting and/or storing products, including waste products. The container assembly has diaphragm with a central aperture and at least one petal. The diaphragm is a portion of the lid or the container. The aperture allows a user to insert one or more fingers (or hand) to pull the first sheet out or alternatively, deposit an item into the container. The diaphragm has one or more slits separating the outer periphery of the diaphragm from portions of the petals, thereby reducing the force required to deflect the diaphragm.

Abstract: The present invention relates to humanized monoclonal antibodies or antigen-binding fragments thereof that specifically bind to human CD40 receptor and induce CD40 signaling independent of Fey mediated CD40 receptor crosslinking. The antibodies of the present invention bind to a CD40 epitope that overlaps with the epitope of the CD40 ligand and can activate human APCs. The present invention also provides for compositions comprising said antibodies and uses for the antibodies and compositions in the treatment of patients suffering from cancer.

Abstract: A diaphragm for a container assembly for dispensing products such as wipes or sheets, or collecting and/or storing products, including waste products. The container assembly has diaphragm with a central aperture and at least one petal. The diaphragm is a portion of the lid or the container. The aperture allows a user to insert one or more fingers (or hand) to pull the first sheet out or alternatively, deposit an item into the container. The diaphragm has one or more slits separating the outer periphery of the diaphragm from portions of the petals, thereby reducing the force required to deflect the diaphragm.

Abstract: In the case of a method or an arrangement for the automatic start up of a first communication terminal (EG A, EG B) configured for voice communication on at least one second communication terminal (CL A, CL B) configured for text communication, the voice communication between communication terminals is conveyed via at least one voice communication server (SCS) and the text communication between communication terminals is conveyed via at least one text communication server (TCS). The at least one voice communication server (SCS) and the at least one text communication server (TCS) exchange information via at least one conversion device (GW). The start up of at least one first communication terminal (CL A, CL B) is effected via the at least one text communication server (TCS), the at least one conversion device (GW) and the at least one voice communication server (SCS) to at least one second voice communication terminal (EG A, EG B).

Abstract: The present invention relates to methods for treating medical conditions and/or disorders characterized by uncontrolled or abnormal expression of members of the IL1R3 signaling pathway such as IL-1?, IL-I?, IL-33, IL-36, IL1RA and/or IL1R3, as well as variants thereof. More specifically, the present invention relates to anti-IL1R3 antibodies for use in the treatment of an IL1R3-mediated inflammatory condition and/or disorder in a subject. Such conditions and disorders include but are not limited to inflammatory diseases, immune disorders, fibrotic disorders, eosinophilic disorders, infection, pain, a central nervous system disorder, an ophthalmologic disorder, Hereditary Systemic Inflammatory Diseases, and Systemic and Local Inflammatory Diseases and cancer associated chronic inflammation.

Abstract: In the case of a method or an arrangement for the automatic start up of a first communication terminal (EG A, EG B) configured for voice communication on at least one second communication terminal (CL A, CL B) configured for text communication, the voice communication between communication terminals is conveyed via at least one voice communication server (SCS) and the text communication between communication terminals is conveyed via at least one text communication server (TCS). The at least one voice communication server (SCS) and the at least one text communication server (TCS) exchange information via at least one conversion device (GW). The start up of at least one first communication terminal (CL A, CL B) is effected via the at least one text communication server (TCS), the at least one conversion device (GW) and the at least one voice communication server (SCS) to at least one second voice communication terminal (EG A, EG B).

Abstract: A vehicle rim is provided having a rim body and at least one capacitor. The rim body has a hub region, a rim bed and a connection region that connects the hub region to the rim bed. The rim body forms at least a part of a housing of the capacitor.